As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Content to be used in accordance with local CPO guidelines
Overall survival (OS) results from the Phase III MONALEESA-2 (ML)-2 trial of postmenopausal patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
Gabriel N. Hortobagyi
Presentation # LBA17_PR
Sept 19, 2021 | 2:10 PM CEST
Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials
Peter A. Fasching
Presentation # 233P – Poster
Sept 16, 2021 | 8:30 AM CEST
Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) + endocrine therapy (ET) in Asian patients (pts) with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC)
Yoon Sim Yap
Presentation # 232P – Poster
Sept 16, 2021 | 8:30 AM CEST
Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study
Thomas Decker
Presentation # 247P – Poster
Sept 16, 2021 | 8:30 AM CEST
Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial
Luca Malorni
Presentation # 292P – Poster
Sept 16, 2021 | 8:30 AM CEST
Cardiovascular disease (CVD) and health care utilization (HCU) in patients (pts) with HR+, HER2 negative (HER2-) advanced breast cancer (ABC) on endocrine therapy with or without CDK4/6 inhibitor (CDK4/6i): A retrospective cohort study
Susan Dent
Presentation # 324P – Poster
Sept 16, 2021 | 8:30 AM CEST
Antineoplastic (ANP) Therapies (Tx) After Alpelisib (ALP) or Placebo (PBO) + Fulvestrant (FUL) in Patients (Pts) With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–), PIK3CA-Mutated (Mut) Advanced Breast Cancer (ABC): An Analysis From SOLAR-1
Fabrice André
Presentation # 309P – Poster
Sept 16, 2021 | 8:30 AM CEST
BOLERO-5: A phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER+/HER2- advanced breast cancer
Zhimin Shao
Presentation # 238P – Poster
Sept 16, 2021 | 8:30 AM CEST
A phase II study of LAG525 in combination with spartalizumab (PDR001), PDR001 and carboplatin (Carbo), or Carbo, as first- or second-line therapy in patients (Pts) with advanced (Adv) triple-negative breast cancer (tnbc)
Lisa A. Carey
Presentation # 275P – Poster
Sept 16, 2021 | 8:30 AM CEST
